A report was issued from Dublin involving Alnylam Pharmaceuticals on August 28, 2025.
1 report, 1 independent
Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A report was issued from Dublin involving Alnylam Pharmaceuticals on August 28, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.
- Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.
-
Dublin
capital and largest city of Ireland
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireNext Generation Drug Conjugates Market Report 2025-2035, with Profiles of Advanced Accelerator Applications, Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Geron, & Ionis Pharmaceuticals